Zasocitinib for psoriatic arthritis in adults
Treatments studied
Part of Bones, joints & muscles, Skin clinical trials.
This study tests an oral medicine called zasocitinib for people with psoriatic arthritis who have not had enough relief from other treatments. It may help reduce joint pain and skin symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with psoriatic arthritis for at least 3 months.
- You currently have at least 3 tender or swollen joints.
- You have at least one patch of plaque psoriasis (raised, red, scaly skin) that is 2 cm or larger, or psoriasis-related nail changes.
- You have tried and not responded well to at least one previous treatment (like NSAIDs, methotrexate, or a biologic).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an oral medication called zasocitinib for adults with psoriatic arthritis who have not tried biologic medicines before. It aims to see if the drug can improve joint pain, swelling, and skin symptoms.
This study is for people with psoriatic arthritis who have already completed a year-long treatment with zasocitinib or a similar medicine in a previous study. It tests whether continuing to take zasocitinib remains safe and helpful over a longer time.
This trial tests a new oral medicine (HS-10374) for people with active psoriatic arthritis who have not responded well to standard treatments. It compares the drug to a placebo to see if it reduces joint pain, swelling, and skin symptoms.
This study tests targeted medications for people with active psoriatic arthritis (PsA) who have already tried 1 or 2 other advanced treatments without success or couldn't tolerate them. The goal is to see if these newer options can better control joint pain and skin symptoms.
This study tests how well upadacitinib (a pill taken daily) works for people with active psoriatic arthritis that also affects the spine. It is for those who have not responded well enough to other treatments like NSAIDs or biologics.
This study tests how well a medicine called Risankizumab works for people with psoriatic arthritis. It is for adults who have had symptoms for at least 6 months and have not had enough help from at least one other arthritis medicine.
Hear when a new Psoriatic Arthritis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.